Selecting Patients for KIT Inhibition in Melanoma
For many years, melanoma has been regarded as a single disease in terms of therapeutic considerations. The more recent identification of multiple molecular mechanisms underlying the development, progression, and prognosis of melanoma has led to a new paradigm for the management of this disease, has created new therapeutic opportunities, and has led to improved clinical outcomes. Such advances, however, are dependent upon methods that can reproducibly identify key molecular alterations within an individual tumor, define clinically relevant genetic subgroups of disease, and permit improved patient selection for targeted therapies. Melanomas harboring genetic alterations of KIT have been demonstrated to constitute one such molecular subgroup of disease. In this chapter, we will discuss the biology of KIT in melanoma, review the rationale for and clinical data regarding KIT inhibition in melanomas harboring activating alterations of KIT , propose guidelines for the selection of patients for KIT inhibitor therapy, and, finally, present laboratory methods for KIT assessment in melanoma.
- Adhesion Signaling Through Integrins
- Simultaneous Flow Cytometric Detection of DNA and Cellular Protein Molecules
- Measurement of Estrogen Receptor Status by Immunocytochemistry in Paraffin Wax Sections
- Cell Motility, Adhesion, Homing, and Migration Assays in the Studies of Tyrosine Kinases
- All-Liquid Separations, Protein Microarrays, and Mass Spectrometry to Interrogate Serum Proteomes: An Application to Serum Glyco
- Myeloperoxidase Promoter Region Polymorphism and Lung Cancer Risk
- Multiple Labeling Techniques for Fluorescence Microscopy
- A Nested RT-PCR Assay to Detect BCR/abl
- 人肝癌细胞与抑癌基因的关系
- Immunoprecipitation to Determine JAK Kinase Activation in Response to Interleukins in Ovarian Cancer